We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
A2M
  • premium

    TISSUE

  • CELL

  • PATHOLOGY

PATHOLOGY ATLAS MELANOMA

GENE/PROTEIN

Antibody validation

Dictionary

Melanoma

MELANOMA - Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival, using best separation (to the left) and median separation (to the right). Patients were divided based on level of expression into one of the two groups "low" or "high". Below each Kaplan-Meier plot, corresponding expression cutoff, 5-year survival for patients with high expression, 5-year survival for patients with low expression and log-rank P value are displayed. For melanoma and glioma, 3-year survival is shown. The survival analysis is described in Assays & Annotation.

The tabs at the top of the survival analysis section can be used to switch between the different cancer subtypes.

Best separation

Median separation

Expression cutoffi

5-year survival for patients with higher expression than the expression cutoff.

174.5 FPKM 132.4 FPKM

3-year survival highi

5-year survival for patients with higher expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

0% 35%

3-year survival lowi

5-year survival for patients with lower expression than the expression cutoff.

For melanoma and glioma, 3-year survival is shown.

52% 22%

Log-rank P valuei

Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.

2.38e-1 6.61e-1

Interactive survival scatter plot (individual patient data)i

The Scatter Survival plot shows the clinical status for all individuals in the patient cohort, based on the same data as in the Kaplan-Meier plots. Living patients are shown in blue and deceased patients in red. The x-axis shows the expression levels (FPKM) of the investigated gene at the time of diagnosis and the y-axis shows the number of years of survival (living years) after the diagnosis.

Individual patient data is displayed in an interactive plot and can be filtered by clicking on one or several category buttons to the left. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be changed to "x linear" by clicking on the "x log" button on the left. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.




Stage:



TCGA RNA samplesi

RNA-seq data is reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .

Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.

Average FPKM

244.3

Number of samples

102

Samples

Sample

Description

FPKM

TCGA-BF-A3DJ-01A 36 years, female, white, stage:iiib 2810.6
TCGA-EB-A42Z-01A 49 years, male, asian, stage:iiic 1226.3
TCGA-ER-A2NF-01A 53 years, male, white, stage:iiib 1099.1
TCGA-D9-A4Z5-01A 68 years, male, white, stage:iib 1093.6
TCGA-EB-A551-01A 78 years, female, white, stage:iiic 1068.8
TCGA-EB-A3XB-01A 63 years, male, white, stage:ii 1031.8
TCGA-IH-A3EA-01A 61 years, male, white, stage:iic 1000.2
TCGA-GN-A263-01A 24 years, male, white, stage:iv 754.9
TCGA-BF-AAOX-01A 83 years, male, white, stage:iic 715.1
TCGA-EB-A3HV-01A 37 years, male, white, stage:iic 538.7
TCGA-EB-A4XL-01A 56 years, female, white, stage:iic 510.7
TCGA-ER-A19T-01A 51 years, male, white, stage:iv 450.0
TCGA-GN-A8LN-01A 68 years, male, white, stage:iic 446.1
TCGA-D9-A3Z4-01A 54 years, male, white, stage:iiic 404.4
TCGA-XV-A9W5-01A 51 years, male, white, stage:i/ii nos 383.7
TCGA-FW-A5DX-01A 71 years, male, white, stage:iiic 380.9
TCGA-BF-A5EO-01A 65 years, male, white, stage:iic 373.4
TCGA-FR-A2OS-01A 49 years, female, white, stage:iic 347.1
TCGA-EB-A41A-01A 90 years, male, white, stage:iic 345.1
TCGA-BF-A5EQ-01A 63 years, male, white, stage:iic 312.4
TCGA-EB-A82B-01A 58 years, female, asian, stage:iii 311.6
TCGA-FR-A726-01A 90 years, male, white, stage:iic 310.3
TCGA-ER-A42H-01A 77 years, male, white 292.0
TCGA-BF-AAOU-01A 73 years, female, white, stage:iic 283.0
TCGA-EB-A3XF-01A 57 years, male, white, stage:iic 282.2
TCGA-EB-A51B-01A 53 years, male, white, stage:iic 255.4
TCGA-EB-A1NK-01A 48 years, male, white, stage:iic 245.8
TCGA-EB-A431-01A 34 years, male, white, stage:iic 245.3
TCGA-EB-A97M-01A 66 years, male, white, stage:iic 242.2
TCGA-EB-A85I-01A 66 years, male, white, stage:iic 234.2
TCGA-BF-AAP8-01A 58 years, male, white, stage:iic 230.1
TCGA-D9-A4Z2-01A 50 years, male, white, stage:iiic 226.7
TCGA-BF-A1PX-01A 56 years, male, white, stage:iiib 219.8
TCGA-EB-A3Y6-01A 56 years, female, white, stage:iic 216.7
TCGA-EB-A57M-01A 56 years, male, asian, stage:iiib 216.2
TCGA-GF-A769-01A 39 years, male, white, stage:iic 214.9
TCGA-GF-A2C7-01A 48 years, male, white, stage:iic 205.0
TCGA-EB-A44P-01A 58 years, female, white, stage:iic 199.3
TCGA-FS-A1ZN-01A 43 years, male, white, stage:iiia 194.3
TCGA-EB-A4IS-01A 77 years, male, white, stage:iib 181.5
TCGA-EB-A6QZ-01A 76 years, female, white, stage:iia 178.5
TCGA-EB-A299-01A 63 years, male, white, stage:iia 178.0
TCGA-EB-A5VU-01A 56 years, male, asian, stage:iiib 175.4
TCGA-D3-A5GT-01A 43 years, male, white, stage:iiic 173.6
TCGA-GN-A4U5-01A 61 years, female, white, stage:ib 169.4
TCGA-EB-A3XC-01A 74 years, male, white, stage:iic 152.9
TCGA-XV-A9W2-01A 81 years, male, white, stage:i 149.7
TCGA-EB-A3XD-01A 53 years, female, white, stage:iic 143.3
TCGA-EB-A550-01A 75 years, female, white, stage:iic 142.9
TCGA-BF-AAP6-01A 55 years, male, white, stage:iii 136.6
TCGA-BF-AAP4-01A 61 years, male, white, stage:iic 132.9
TCGA-EB-A3XE-01A 77 years, female, white, stage:iia 132.0
TCGA-BF-A5ES-01A 76 years, female, white, stage:iic 129.7
TCGA-XV-AAZV-01A 56 years, female, white, stage:ii 120.9
TCGA-XV-AAZY-01A 76 years, female, white, stage:iiic 114.1
TCGA-EB-A44N-01A 59 years, male, white, stage:iic 112.0
TCGA-ER-A196-01A 64 years, female, white, stage:iic 110.1
TCGA-BF-A3DN-01A 81 years, female, white, stage:iiic 106.1
TCGA-EB-A5FP-01A 65 years, female, white, stage:iv 105.9
TCGA-FR-A3R1-01A 69 years, male, white, stage:iic 102.9
TCGA-EB-A44O-01A 69 years, male, white, stage:iib 101.9
TCGA-EB-A85J-01A 66 years, female, white, stage:iib 98.7
TCGA-BF-AAP7-01A 76 years, female, white, stage:iic 96.1
TCGA-ER-A19K-01A 79 years, female, white, stage:iic 94.0
TCGA-BF-A5ER-01A 63 years, male, white, stage:iic 91.3
TCGA-BF-AAP2-01A 62 years, male, white, stage:iib 85.7
TCGA-GN-A26C-01A 77 years, male, white, stage:iiic 75.6
TCGA-FR-A728-01A 54 years, female, white, stage:iiib 66.6
TCGA-YG-AA3N-01A 67 years, male, stage:iic 66.5
TCGA-EB-A4OY-01A 65 years, female, white, stage:iiib 63.6
TCGA-EB-A5SE-01A 73 years, male, white, stage:iib 61.0
TCGA-WE-A8K4-01A 85 years, male, white, stage:iib 60.2
TCGA-D9-A4Z3-01A 73 years, female, white, stage:iiic 57.6
TCGA-HR-A5NC-01A 90 years, female 53.1
TCGA-BF-A5EP-01A 75 years, female, white, stage:iiic 52.9
TCGA-EB-A42Y-01A 73 years, female, asian, stage:iic 52.9
TCGA-BF-A3DL-01A 84 years, female, white, stage:iiib 49.7
TCGA-BF-A1Q0-01A 80 years, male, white, stage:iic 48.6
TCGA-BF-A1PU-01A 46 years, female, white, stage:iic 48.1
TCGA-ER-A194-01A 77 years, male, white 48.1
TCGA-EB-A41B-01A 76 years, female, white, stage:iic 45.6
TCGA-BF-A9VF-01A 77 years, male, white, stage:iic 43.5
TCGA-EB-A4OZ-01A 42 years, female, white, stage:iiic 43.2
TCGA-EB-A24C-01A 56 years, male, white 42.5
TCGA-EB-A6QY-01A 71 years, male, white, stage:iic 42.2
TCGA-BF-A3DM-01A 63 years, male, white, stage:iia 35.9
TCGA-EB-A5SF-01A 78 years, female, white, stage:iic 35.5
TCGA-EB-A4IQ-01A 42 years, female, asian, stage:iiib 35.0
TCGA-EB-A3Y7-01A 86 years, female, white, stage:iiib 33.6
TCGA-EB-A4P0-01A 82 years, male, white, stage:iic 33.5
TCGA-XV-A9VZ-01A 90 years, female, white, stage:ii 31.8
TCGA-BF-AAP1-01A 86 years, male, white, stage:iic 31.5
TCGA-XV-AAZW-01A 62 years, female, white, stage:ii 30.9
TCGA-EB-A5UM-01A 48 years, female, white, stage:iic 27.1
TCGA-EB-A553-01A 62 years, male, white, stage:iic 26.8
TCGA-ER-A2NB-01A 57 years, male, white, stage:iiib 25.5
TCGA-BF-A1PZ-01A 71 years, female, white, stage:iib 24.4
TCGA-EB-A6R0-01A 58 years, female, white, stage:iic 23.8
TCGA-EB-A24D-01A 72 years, male, white, stage:iiib 23.2
TCGA-DA-A960-01A 73 years, male, white, stage:iib 18.2
TCGA-BF-A1PV-01A 74 years, female, white, stage:iic 15.7
TCGA-EB-A82C-01A 70 years, female, asian, stage:iic 12.4
Show all

MELANOMA - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody HPA002265

Antibody CAB017621

 Antibody staining
  High
  Medium
  Low
  Not detected
   
 Intensity
  Strong
  Moderate
  Weak
  Negative
   
 Quantity
  >75%
  75%-25%
  <25%
  Rare
  Negative
   
 Location
  Cytoplasmic/membranous,nuclear
  Cytoplasmic/membranous
  Nuclear
  None
   

Click images for details















































Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.